Although humoral responses against CTL epitope peptides from lymphocyte-specific protein tyrosine kinase (Lck) antigen have been observed in the majority of healthy donors and cancer patients, the biological activity of the antibody has not been determined. We investigated the biological activity of mAb against CTL -
| INTRODUCTION
We previously reported that the IgG against CTL epitope peptides from Lck antigen have been observed in the majority of healthy donors and cancer patients in correlation with the overall survival of cancer patients. 1 We also reported that an increase in the IgG responses to the vaccinated peptides were favorable for the overall survival of cancer patients under PPV, in which four of 31 warehouse peptides were selected by pre-existing peptide-specific IgG levels. 2, 3 Among the warehouse peptides for PPV, peptides derived from Lck have been used most frequently for PPV for advanced cancer patients, with favorable clinical outcomes. 2, 3 Lymphocyte-specific protein tyrosine kinase is a member of the Src family of non-receptor protein tyrosine kinases expressed in both activated T lymphocytes and metastatic cancer cells with oncogenic properties in human cancers. 4, 5 Lymphocytespecific protein tyrosine kinase is pivotal for Tregs and program death-1-positive T-cell activities. 6, 7 The Lck gene was reported to encode CTL epitope peptides that were cytotoxic to tumor cells from metastatic cancer patients. 8 Immunoglobulin G reactive to Lck peptide at positions 486-494
(Lck-486) was found to be expressed in some metastatic tumor cells and T cells at the tumor site, but not expressed in tumor cells from non-metastatic primary tumor cells. [1] [2] [3] In the present study, we investigated the biological activity of a mAb reacting to the Lck peptide at positions 486-494 (anti-Lck-486 mAb), and showed it had antitumor activity.
| MATERIALS AND METHODS

| Antibody production and purification
The hybridoma clone producing IgG2b specific to the Lck-486 peptide (TFDYLRSVL), which is shared by both humans and mice, was carried out by Cell Engineering Corp. (Osaka, Japan). The hybridoma producing IgG2b reactive to the SART3 peptide at positions 109-117 (SART3-109) (VYDYNCHVDL, which is different from the mouse SART3 sequence at position 117 (D to E in the mouse SART3 gene as reported), 9 was also provided by the study. Both peptides were able to induce peptide-specific CTLs in HLA-A24 + cancer patients. 3, 10 We measured the levels of IgG produced by these hybridoma clones reactive to Lck-486 or to SART3-109 by carrying out a multiplex bead suspension array using the Luminex system (Luminex, Austin, TX, USA), as described.
11
The specificity of the anti-Lck-486 and that of the anti-SART3-109 mAb was confirmed by competition assay ( Figure S1 ). For the competition assay, 10 000-fold diluted antibody was incubated with 100 lL peptide-coupled color-coded beads and 5 lL each of the corresponding peptides (10 lg/mL) for 1.5 hours at 30°C. The binding of anti-peptide IgG was detected by the same method as that described above. 1 For purification, the cloned cells were cultured with hybridoma serum-free medium (Life Technologies, Carlsbad, CA, USA 12 The sequence of SART2-161 peptide is shared by humans and mice.
| Generation of myeloid DCs
Marrow from the bones (femurs and tibias) was flushed and collected into RPMI medium. Ammonium chloride lysis buffer was added to lyse red blood cells, and then the bone marrow cells were washed and suspended in RPMI medium. These cells were incubated in the presence of 500 U/mL granulocyte/macrophage colony-stimulating factor and 1000 U/mL interleukin-4 for 48 hours for induction of immature DCs based on the methods reported. 13 
| Animal study
All animal experiments were approved by the Animal Experiments For the second series of experiments investigating the antitumor effect of anti-Lck-486 mAb injection prior to the peptide vaccine, the treatment was started on day 3; in this experiment, the mice were killed on day 21.
| Vaccination
The Lck-486 and SART2-161 peptides were dissolved in Meylon 7%
injection (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan), then diluted with Otsuka Distilled Water (Tokyo, Japan). The vaccine was formulated with incomplete Freund's adjuvant (Montanide ISA-51VG; Seppic, Paris, France) and peptide solution at a 1:1 ratio.
| Antibodies and cell surface marker analysis
For the staining surface marker of DCs and TILs, APC anti-mouse CD4, FITC-CD11c, APC-CD40, PerCP/Cy5.5-CD80, and PE/Cy7-CD86, and the Treg flow kit were purchased from BioLegend Japan (Tokyo). Fluorescein isothiocyanate-labeled mouse CD8 was purchased from MBL (Nagoya, Japan 
| Cytotoxic T-lymphocyte assay
Mice were inoculated s.c. with 100 lg Lck486 peptide plus incomplete
Freund's adjuvant to the flank once a week for 6 weeks, as reported previously. 10 Spleens were harvested and homogenized into single cell suspensions using two pairs of slide glasses, and a 100-lm cell strainer (Greiner Bio-One) was used to remove debris. Cells were centrifuged and ammonium chloride lysis buffer was added to lyse red blood cells.
The cells were washed and resuspended in RPMI medium for counting.
Cells were resuspended at 2 9 10 7 /mL in RPMI complete media and were incubated with or without 10 lg/mL Lck486 peptide for 4 days at 37°C. After incubation, the cells were harvested and tested for their ability to produce c-interferon in response to Lck486 peptide, or without peptide as a negative control. Antigen-specific c-interferon secretion after 18 hours of incubation was determined by ELISPOT assay in accordance with the manufacturer's instructions. All assays were carried out in triplicate, at minimum, and spots were counted by an ELI-SPOT reader (CTL-ImmunoSpot S5 series, Cellular Technology Ltd., Cleveland, OH, USA). For in vitro stimulation of spleen cells, the same method of preparation was used.
| Statistical analysis
Two-sided P-values <.05 were considered significant. All statistical analyses were undertaken using JMP Pro 11.0 software (SAS Institute, Cary, NC, USA).
| RESULTS AND DISCUSSION
3.1 | Cytotoxic T lymphocytes specific for Lck468 in this mouse system
To facilitate better understanding of the T cell-recognition of Lck486 peptide, we tested whether Lck486 peptide-specific CTLs were detectable in a murine system measured by ELISPOT assay. We found that Lck486 peptide-specific CTLs were detected by ELISPOT assay in spleen cells when mice were vaccinated with Lck468 peptide. The number of spots for the immunized group and the nonimmunized control group were 13 AE 4.5 and 3 AE 1.9 (P = .006),
respectively. In addition, it was detectable when spleen cells were stimulate by addition of Lck468 peptide in vitro. The number of spots for the peptide-stimulated group and the control group were 175 AE 36.6 and 48 AE 21.5 (P = .001), respectively. 
| Effect of anti-Lck486 mAb injection prior to peptide vaccination
We then hypothesized that more potent antitumor activity could be obtained by an injection of the antibody prior to the vaccination, given the induction of matured DCs at regional lymph nodes through the activation of CD80/CD86 and the CD28 pathway, 16 peptide-specific manner. These issue needs to be further studied in the near future by a relatively large-scale study.
Since 1989, numerous studies have been undertaken on the potential of Lck antigen as a druggable molecule for cancer therapy, but, to the best of our knowledge, the efforts to achieve this have not been successful. 17, 18 This failure might be due in part to the unique properties of Lck, which is involved in both immune activation and oncogenesis. 
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